Dr. Norman Sharpless Brings Proven Scientific Leadership to the National Cancer Institute

Statement by ASCO President Bruce E. Johnson, MD, FASCO
For immediate release
June 12, 2017


Mary Rappaport

"The American Society of Clinical Oncology (ASCO) congratulates Dr. Norman "Ned" Sharpless on his appointment as director of the National Cancer Institute (NCI). ASCO is encouraged that NCI will have at its helm an accomplished researcher with experience leading a wide range of clinical and translational research endeavors focused on bringing new insights into cancer prevention and treatment.

"Under Dr. Sharpless' leadership, NCI will be tasked with delivering on the promise of precision medicine and the recently funded Beau Biden Cancer Moonshot, for which the first of seven years of scheduled funding has been provided. At the same time, the agency faces potential budget cuts that would disable cancer research progress. With recent research showing Americans have gained millions of years from federally funded cancer trials, NCI’s work needs to be nurtured and sustained.

“ASCO looks forward to working with Dr. Sharpless and the dedicated professionals at NCI in ensuring the United States’ preeminence in biomedical research. We remain committed to NCI’s mission and will continue to advocate for continued support of our nation’s critical investment in its life-saving work.”

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube. Visit ascoaction.asco.org for the latest cancer-policy developments and read our cancer policy issue briefs for an overview of key policy issues.